Hi GrowI had to look back on my original DD post, worth a look...

Hi Grow

I had to look back on my original DD post, worth a look for some history if you haven't read it. In the HealthKick Podcast Brian Leedman did earlier this year he is quoted as to saying "phase 1 is effectively a safety study in humans".
Except for the case of Glaucoma, in which they will be able to go straight into Glaucoma patients.
This was fully confirmed in the below announcement on the 23rd of June:


So prong 1,2, and 3 should work like this
- Ph1 safety study all encompassing (Alzheimer's, MS, PF)
- Ph2 studies in Alzheimer's, Multiple Sclerosis, and Pulmonary Fibrosis - Note that in the HealthKick podcast Leedman did say that after a general safety study was done they could go into Fibrosis patients even though this hasn't been stated in an Ann to my knowledge

prong 4 should work like this
- Ph1 straight into Glaucoma Patients
- Ph2 into Glaucoma patients

Company has yet to address timelines for Pulmonary Fibrosis and Multiple Sclerosis Ph2 trials, but I hope now that preclinical work is done they can all begin next year